Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 459.0
(-6.32%)
USD 459.0
(-6.32%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 738.8 Million USD | 60.4% |
| 2022 | 460.6 Million USD | 30.44% |
| 2021 | 353.1 Million USD | 25.76% |
| 2020 | 280.77 Million USD | 67.63% |
| 2019 | 167.5 Million USD | 34.69% |
| 2018 | 124.36 Million USD | 11.2% |
| 2017 | 111.83 Million USD | 44.1% |
| 2016 | 77.6 Million USD | 38.37% |
| 2015 | 56.08 Million USD | 81.8% |
| 2014 | 30.84 Million USD | 118.05% |
| 2013 | 14.14 Million USD | -53.56% |
| 2012 | 30.46 Million USD | -72.9% |
| 2011 | 112.43 Million USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 8000.00 USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 4.34 Million USD | -34.46% |
| 2001 | 6.63 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 813.1 Million USD | 10.06% |
| 2024 Q2 | 914.6 Million USD | 12.48% |
| 2024 Q3 | 1.07 Billion USD | 18.06% |
| 2023 Q1 | 535.1 Million USD | 16.17% |
| 2023 Q3 | 688.7 Million USD | 14.12% |
| 2023 FY | 738.8 Million USD | 60.4% |
| 2023 Q2 | 603.5 Million USD | 12.78% |
| 2023 Q4 | 738.8 Million USD | 7.27% |
| 2022 FY | 460.6 Million USD | 30.44% |
| 2022 Q2 | 367.7 Million USD | 8.5% |
| 2022 Q3 | 388.2 Million USD | 5.58% |
| 2022 Q4 | 460.6 Million USD | 18.65% |
| 2022 Q1 | 338.9 Million USD | -4.02% |
| 2021 Q2 | 321.62 Million USD | 7.61% |
| 2021 FY | 353.1 Million USD | 25.76% |
| 2021 Q1 | 298.86 Million USD | 6.44% |
| 2021 Q3 | 333.45 Million USD | 3.68% |
| 2021 Q4 | 353.1 Million USD | 5.89% |
| 2020 Q4 | 280.77 Million USD | 14.39% |
| 2020 Q2 | 219.21 Million USD | 17.17% |
| 2020 Q3 | 245.46 Million USD | 11.97% |
| 2020 FY | 280.77 Million USD | 67.63% |
| 2020 Q1 | 187.08 Million USD | 11.69% |
| 2019 Q1 | 136.69 Million USD | 9.92% |
| 2019 FY | 167.5 Million USD | 34.69% |
| 2019 Q4 | 167.5 Million USD | 3.2% |
| 2019 Q3 | 162.3 Million USD | 13.49% |
| 2019 Q2 | 143.01 Million USD | 4.62% |
| 2018 Q1 | 117.34 Million USD | 4.93% |
| 2018 Q4 | 124.36 Million USD | 0.17% |
| 2018 Q2 | 115.02 Million USD | -1.98% |
| 2018 Q3 | 124.15 Million USD | 7.93% |
| 2018 FY | 124.36 Million USD | 11.2% |
| 2017 Q2 | 92.26 Million USD | 12.49% |
| 2017 Q4 | 111.83 Million USD | 13.89% |
| 2017 FY | 111.83 Million USD | 44.1% |
| 2017 Q1 | 82.02 Million USD | 5.69% |
| 2017 Q3 | 98.19 Million USD | 6.43% |
| 2016 FY | 77.6 Million USD | 38.37% |
| 2016 Q3 | 71.79 Million USD | 7.82% |
| 2016 Q4 | 77.6 Million USD | 8.09% |
| 2016 Q2 | 66.58 Million USD | 5.36% |
| 2016 Q1 | 63.2 Million USD | 12.69% |
| 2015 Q3 | 49.19 Million USD | 16.82% |
| 2015 Q1 | 34.08 Million USD | 10.51% |
| 2015 Q2 | 42.11 Million USD | 23.54% |
| 2015 FY | 56.08 Million USD | 81.8% |
| 2015 Q4 | 56.08 Million USD | 14.0% |
| 2014 Q1 | 11.26 Million USD | -20.4% |
| 2014 Q3 | 16.75 Million USD | 39.82% |
| 2014 FY | 30.84 Million USD | 118.05% |
| 2014 Q4 | 30.84 Million USD | 84.13% |
| 2014 Q2 | 11.98 Million USD | 6.4% |
| 2013 Q4 | 14.14 Million USD | 4.46% |
| 2013 Q3 | 13.54 Million USD | -30.58% |
| 2013 Q2 | 19.5 Million USD | -9.4% |
| 2013 Q1 | 21.53 Million USD | -29.32% |
| 2013 FY | 14.14 Million USD | -53.56% |
| 2012 Q3 | 86.27 Million USD | -1.74% |
| 2012 FY | 30.46 Million USD | -72.9% |
| 2012 Q1 | 129.59 Million USD | 15.27% |
| 2012 Q4 | 30.46 Million USD | -64.69% |
| 2012 Q2 | 87.8 Million USD | -32.25% |
| 2011 Q2 | 52.62 Million USD | 195.36% |
| 2011 FY | 112.43 Million USD | 0.0% |
| 2011 Q4 | 112.43 Million USD | 66.18% |
| 2011 Q3 | 67.65 Million USD | 28.57% |
| 2011 Q1 | 17.81 Million USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | 8000.00 USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | -856.61 Million USD | 0.0% |
| 2009 Q4 | - USD | 100.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q1 | 4.58 Million USD | 5.43% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | 3.42 Million USD | -20.74% |
| 2003 Q4 | - USD | -100.0% |
| 2003 Q2 | 4.32 Million USD | -5.67% |
| 2002 Q3 | 4.25 Million USD | -6.49% |
| 2002 Q4 | 4.34 Million USD | 2.26% |
| 2002 Q2 | 4.54 Million USD | -12.17% |
| 2002 Q1 | 5.17 Million USD | -21.97% |
| 2002 FY | 4.34 Million USD | -34.46% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | 3.36 Million USD | 0.0% |
| 2001 FY | 6.63 Million USD | 0.0% |
| 2001 Q4 | 6.63 Million USD | 97.38% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -6044.378% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -3772.929% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -1137.604% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -7511.787% |
| bluebird bio, Inc. | 22.91 Million USD | -3123.526% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -26089.295% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -91.466% |
| Myriad Genetics, Inc. | 20.1 Million USD | -3575.622% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -1828.982% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -854.423% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 91.12% |
| Waters Corporation | 516.23 Million USD | -43.113% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 85.48% |
| Biogen Inc. | 2.52 Billion USD | 70.768% |
| Nektar Therapeutics | 16.1 Million USD | -4488.535% |
| Perrigo Company plc | 1.14 Billion USD | 35.244% |
| Dynavax Technologies Corporation | 53.29 Million USD | -1286.376% |
| Illumina, Inc. | 587 Million USD | -25.86% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -7023.024% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -1654.453% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 33.272% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -6617.585% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 71.37% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -1025.825% |
| FibroGen, Inc. | 41.56 Million USD | -1677.457% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 28.341% |
| OPKO Health, Inc. | 65.69 Million USD | -1024.557% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -728.753% |
| Exelixis, Inc. | 17.32 Million USD | -4164.85% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 71.186% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -4781.401% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 30329.133% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -2499.12% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -128.831% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -9457.568% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -478.992% |
| Blueprint Medicines Corporation | 21.22 Million USD | -3381.129% |
| Insmed Incorporated | 83.24 Million USD | -787.469% |
| TG Therapeutics, Inc. | 39.82 Million USD | -1755.209% |
| Incyte Corporation | 62.97 Million USD | -1073.22% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -124.628% |